Larosa Joseph J's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 21, 2026
- Accession no.
- 0001238303-26-000002
- Filed
- Aug 21, 2026, 4:01 PM ET
- Trade date
- Aug 19, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Larosa Joseph JCIK 0001238303 | Officer (EVP General Counsel and Secret) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Common Stock | MOption exerciseAcquired | +12,282 | $381.92 | +$4,690,741.44 | 45,392 | Direct | |
| Aug 19, 2026 | Common Stock | FTax withholdingDisposed | −9,019 | $830.15 | −$7,487,122.85 | 36,373 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Common Stock | MOption exerciseDisposed | −12,282 | $0.00 | $0 | 12,283 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.